Dr. Perez Discusses Obesity as a Predictive Marker

Edith A. Perez, MD
Published: Monday, Jan 16, 2012

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses a large study of 3017 patients with HER2-positive breast cancer that examined if body mass could predict outcomes.

The study found that obese patients experienced worse outcomes than normal weight or overweight patients. These patients experienced larger tumors size, greater lymph node involvement, and worse tumor characteristics overall. However, the study noted that response to trastuzumab (Herceptin) remained the same, regardless of the patient's body mass index.

Perez notes that it is reassuring that the response to trastuzumab remains the same but recommends that patients maintain a healthy weight, since the tumors had worse characteristics overall with an increased BMI.
Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses a large study of 3017 patients with HER2-positive breast cancer that examined if body mass could predict outcomes.

The study found that obese patients experienced worse outcomes than normal weight or overweight patients. These patients experienced larger tumors size, greater lymph node involvement, and worse tumor characteristics overall. However, the study noted that response to trastuzumab (Herceptin) remained the same, regardless of the patient's body mass index.

Perez notes that it is reassuring that the response to trastuzumab remains the same but recommends that patients maintain a healthy weight, since the tumors had worse characteristics overall with an increased BMI.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x